Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
HOME > BUSINESS
BUSINESS
- Daiichi Sankyo Seeks Label Expansion for Ezharmia into PTCL in Japan
February 1, 2024
- Keytruda/Padcev Filed in Japan for 1st Line Bladder Cancer Treatment: MSD, Astellas
February 1, 2024
- Parmodia Again Tops December GP Rep Promotion Ranking, Dayvigo 5th Month Title Holder for HP
February 1, 2024
- Axcelead DDP Looks to Lift Overseas Sales Ratio to 80%: President
January 31, 2024
- Teva Takeda JVs Curb Shipments of 8 Products in Quake Fallout
January 31, 2024
- Gilead Files Trodelvy for Triple-Negative Breast Cancer in Japan
January 31, 2024
- US FDA Approves Additional CIDP Use for Takeda’s Gammagard Liquid
January 31, 2024
- Takeda’s Hyqvia Nabs European Approval for CIDP Maintenance Therapy
January 31, 2024
- Susmed Drops Reimbursement Request for Insomnia App
January 30, 2024
- Enhertu Gets FDA’s Priority Review for Pan-Tumor Indication: Daiichi Sankyo
January 30, 2024
- Astellas/Pfizer Seeks 1st Line Bladder Cancer Use for Padcev/Keytruda in EU
January 30, 2024
- Eisai Resubmits Ultra-High Dose Mecobalamin in Japan for ALS
January 29, 2024
- Mitsubishi Tanabe Newly Pledges 100 Billion Yen for GHIT Fund
January 29, 2024
- Tecentriq/Cabometyx Cuts Risk of Disease Progression or Death by 35% in CRPC
January 29, 2024
- Towa Begins Priority Supply of 23 APIs, Mostly under Shipment Curbs, to Quake-Hit Area
January 26, 2024
- Shionogi Partners with Niremia Collective to Fund Well-Being Tech Startups
January 26, 2024
- BlueRock In-Licenses Fujifilm’s iPSC Therapy for Ocular Disease
January 25, 2024
- Kyowa Kirin Closes Acquisition of UK Gene Therapy Player Orchard
January 25, 2024
- Takeda’s Cuvitru Now Available in Japan as Its First SC Immunoglobulin
January 25, 2024
- Ono Revs Up to Boost Global Presence, Launches New HR Scheme
January 24, 2024
ページ
On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…